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Impaired revascularization of transplanted islets is a critical
problem that leads to progressive islet loss. Since endothelial
progenitor cells (EPCs) are known to aid neovascularization, we
aimed to enhance islet engraftment by cotransplanting EPCs with
islets. Porcine islets, with (islet-EPC group) or without (islet-only
group) human cord blood–derived EPCs, were transplanted into
diabetic nude mice. The islet-EPC group reached euglycemia by
;11 days posttransplantation, whereas the islet-only group did not.
Also, the islet-EPC group had a higher serum porcine insulin level
than the islet-only group. Islets from the islet-EPC group were more
rapidly revascularized at the early period of transplantation without
increment of ﬁnal capillary density at the fully revascularized graft.
Enhanced revascularization rate in the islet-EPC group was mainly
attributed to stimulating vascular endothelial growth factor-A pro-
duction from the graft. The rapid revascularization by EPC cotrans-
plantation led to better graft perfusion and recovery from hypoxia.
EPC cotransplantation was also associated with greater b-cell pro-
liferation, probably by more basement membrane production and
hepatocyte growth factor secretion. In conclusion, cotransplanta-
tion of EPCs and islets induces better islet engraftment by enhanc-
ing the rate of graft revascularization. These ﬁndings might provide
a directly applicable tool to enhance the efﬁcacy of islet transplan-
tation in clinical practice. Diabetes 61:866–876, 2012
Type 1 diabetes mellitus (T1DM) accounts for5–10% of diabetes and results from the destructionof the b-cells of the pancreas. Patients withT1DM become dependent on insulin for survival,
and therefore strategies for replacing b-cells such as pan-
creas transplantation or islet transplantation have long been
considered to have promise for T1DM (1). Islet transplan-
tation is less invasive than pancreas transplantation, more
physiologic than insulin injection, and may be beneﬁcial for
patients with brittle diabetes via prevention of severe hy-
poglycemic events (2). However, there are several hurdles
with islet transplantation such as limited availability of donor
islets, the immediate destruction of ;50% of transplanted
islets, and impaired revascularization of grafts (2).
Compared with the acinar cells of pancreas, islets are
highly vascularized tissue, and the pivotal role of this
vasculature has been well demonstrated (3–5). However,
isolated islets are supplied with oxygen and nutrients solely
by diffusion immediately after transplantation and are not
fully revascularized until 1 month posttransplantation (6).
Even after 1 month, islets suffer from chronic hypoxia and
ischemia (7). Therefore, a new strategy for facilitating islet
revascularization may be effective for successful islet
transplantation.
Endothelial progenitor cells (EPCs) are circulating
progenitor cells that enhance neovascularization in various
pathophysiologic conditions (8,9). EPCs can be obtained
from the patient’s own peripheral blood or from cord blood,
making EPC-based strategies more accessible and safer
than those using other types of stem/progenitor cells (10,11).
Although there are previous reports demonstrating that
bone marrow–derived endothelial cells are recruited to the
pancreas (12,13) or transplanted islets (14) and that these
cells contribute to angiogenesis, the decreased number and
impaired function of EPCs in diabetic patients suggest that
the recipient-derived EPCs may be poor adjunct cells for
improvement of graft neovascularization (15,16). In this
study, we attempted to demonstrate the therapeutic efﬁcacy
of ex vivo–expanded, cord blood–derived EPC cotrans-
plantation in enhancing islet engraftment and to explain
the underlying mechanism of this strategy.
RESEARCH DESIGN AND METHODS
Islet isolation and culture. Porcine islets were isolated from modern farm
pigs according to previously established protocols (17). Mouse islets were
isolated according to previous reported protocols (18). In brief, pancreata
were harvested, distended with University of Wisconsin solution, and digested
with Liberase DL (Roche Biochemicals, Basel, Switzerland) in a modiﬁed
Ricordi chamber. Islets were separated from nonislet tissue of the pancreas
using University of Wisconsin/OptiPrep density gradient solution in a COBE
2991 cell processor (Gambro BCT, Lakewood, CO). Isolated porcine islets
were cultured in M199 medium (Gibco-BRL, Grand Island, NY), and mouse
islets were culture in RPMI-1640 medium (Gibco-BRL).
EPC isolation and culture. Human EPCs were isolated from umbilical cord
blood obtained during normal birth by the preestablished protocol (19). The in-
stitutional review board of Seoul National University Hospital approved this study
protocol, and all subjects provided informed consent for EPC isolation from their
cord blood. Brieﬂy, mononuclear cord blood cells were harvested via a density
gradient using Histopaque (Sigma, St. Louis, MO) and plated in cell culture dish
with endothelial basal medium-2 (Lonza, Walkersville, MD). The medium was
changed daily for 2–3 weeks after seeding. An EPC colony with a typical cob-
blestone appearance developed after 2 weeks of seeding. The colony was re-
moved by trypsinization and reseeded in gelatin-coated plates. The EPCs from
the third passage were tested for expression of previously reported EPC surface
markers (i.e., positive for platelet endothelial cell adhesion molecule (PECAM)-1,
vascular endothelial growth factor (VEGR) receptor (VEGFR)2, tyrosine kinase
with immunoglobulin-like and endothelial growth factor-like domains [Tie]-2,
vascular endothelial (VE)-cadherin, ulex europaeus agglutinin (UEA)1, CD34, and
von-Willebrand factor [vWF] and negative for CD45, CD3, and CD14) by either
ﬂuorescence-activated cell sorting (BD FACSCalibur; BD-Pharmingen) or
immunostaining. All of the ﬂow cytometry antibodies were from BD Biosciences.
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FIG. 1. Better glycemic control and islet engraftment with EPC cotransplantation. A and B: Cord blood–derived EPCs of passage 3 were harvested and
analyzed for expression of EPC markers by ﬂuorescence-activated cell sorting (A) and immunocytostaining (B). EPCs were negative for CD45, CD3,
and CD14 expression and positive for PECAM-1, VEGFR2, Tie2, UEA1, CD34, VE-cadherin, and vWF expression. C–E: Islets were transplanted into the
kidney capsules of the recipient mice with or without EPCs (n = 6–9 per group). The blood glucose levels (C) and body weights (D) of each group were
measured for 42 days after transplantation.E: The fasting serum porcine insulin level was measured with an immunoradiometric assay at day 35 (n = 5–8
per group). F–J: The graft-bearing kidney was harvested at day 35. F: The upper panel shows hematoxylin-eosin staining of the grafts in the islet-only
and islet-EPC groups. The lower panel shows the insulin-positive area of each group, as determined by the immunostaining. G: The insulin-positive area
was measured and presented as the percentage of a given area (0.72 mm2) (n = 4). H: The graft site of each mouse was analyzed for insulin by q-PCR
with porcine-speciﬁc primers. The data are presented in arbitrary units (AU) after normalization to glyceraldehyde-3-phosphate dehydrogenase, with
the islet-only group set to 1 (n = 4). I: Connective tissue area of the graft was visualized by Col IV together with insulin for b-cells by immunostaining.
J: Endocrine cells of the graft were visualized for glucagon (a-cell), somatostatin (d-cell), and insulin (b-cell) by immunostaining. Scale bars, 100mm. All
data are presented as means6 SE. *P< 0.05 vs. the islet-only group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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FIG. 2. Rapid revascularization of the graft by EPC cotransplantation. A and B: The blood vessels of the graft site were visualized at day 35 using
BS1-lectin and VE-cadherin immunostaining (n = 4). A: Representative images of the immunostaining. The areas in the white dotted rectangle are
shown as magniﬁcation view in the right panel. B: The total area of all vessels, large-vessel (diameter ‡5 mm) and small-capillary (diameter
<5 mm), in the graft were quantiﬁed. C–F: The BS1-lectin–positive blood vessels of the graft were shown from early to late time point (days 3, 14, 21,
and 35). C: Representative images of the immunostaining. D–F: The area of total BS1-lectin–positive vessels (D), branching vessels longer than
30 mm (E), and capillary density (F) were measured in the graft site (n = 4). All quantiﬁcation data of vascular density in B, D, E, and F were
calculated as percent area of the total graft area and then presented as arbitrary units (AU), with the value of the islet-only group set to 1 in B,
with the value of the islet-only group at day 3 set to 1 in D and E, and with the value of the islet-only group at day 14 set to 1 in F. G and H: The
capillary density of the intraislet area at day 21 was visualized with anti-human and anti-pig/mouse PECAM-1 antibodies (red) together with
insulin antibody (green). G: Representative images of the PECAM-1 immunostaining. H: The capillary density positive for PECAM-1 within the
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Islet and EPC coculture. For in vitro experiments, 500 islets from the BALB/c
mice were carefully mixed with 5 3 105 of human cord blood–derived EPCs in
3 mL medium consisting of equal volumes of RPMI-1640 and endothelial basal
medium-2. The cell mixture was maintained for 2 h in a 5% CO2 cell culture
incubator with careful pipetting every 15 min and was then plated on a non-
coated, stirred cell culture dish to inhibit attachment of the cells to the plate.
As a result, some of the EPCs became attached to the surface of the islets. The
cocultured islet-EPC complexes were maintained for 48 h to allow enough time
for the EPCs to cover most of the surface of the islets. As a control, 500 islets
were cultivated alone under the same conditions. For the porcine islet and
human EPC coculture experiments, 1.5 3 105 human EPCs were seeded on the
bottom of the cell culture plate. After these EPCs had attached to the plate, the
hanging-well inserts, where 2,000 islet equivalents (IEQs) of porcine islets had
previously been cultivated, were inserted into the plates to permit the coculture
of the porcine islets and EPCs via transwell membranes. EPCs and porcine
islets were cultivated alone as controls. After 4 days of coculture, the EPCs and
porcine islets from each group were harvested and analyzed for human hepa-
tocyte growth factor (HGF) or porcine VEGF-A by quantitative RT-PCR (q-PCR).
Animal experiments. BALB/c nude mice were purchased from Japan SLC
(Shizuoka, Japan). The animal care and experimental procedures were per-
formed with the approval of the animal care committee of the Seoul National
University Hospital. All mice were maintained in a speciﬁc pathogen-free fa-
cility and fed ad libitum with a standard normal diet (PMI LabDiet; Purina Mills)
and free access to water. Streptozotocin (180 mg/kg; Sigma) was injected via
the peritoneum to induce diabetes in the 10-week-old mice (20). Only the mice
displaying stable hyperglycemia (.500 mg/dL) for 2 weeks were selected
as the transplantation recipients. Porcine islets (7,000 IEQ, with or without
5 3 105 EPCs) were transplanted by careful injection of the cells into the renal
capsules of these mice (21). Random blood glucose levels were measured
from the tail vein with a glucose meter (One Touch Ultra Sensor, Lifescan,
Milpitas, CA), and body weight was recorded for 35 days after transplantation.
Whole blood was collected from the retro-orbital sinus using a capillary tube,
and serum was separated. For functional vessel evaluation, 200 mg tetramethyl
rhodamine isothiocyanate (TRITC)-bandeiraea simplicifolia (BS)1-lectin (Sigma)
was injected via the tail vein 1 h before harvesting the tissue. To assess the
degree of tissue hypoxia, 60 mg/kg hypoxia probe (Hypoxyprobe, Burlington,
MA) was injected into the tail vein 30 min before tissue harvesting. Porcine insulin
was detected using an immunoradiometric assay (DIASourceImmunoAssays,
Nivelles, Belgium). For the quantitative analysis of VEGF-A, insulin, and HGF in
vivo, the graft site was harvested and evaluated using q-PCR with porcine-speciﬁc
primers for VEGF-A and insulin, and with primers that detected human, porcine,
and mouse HGF.
Immunostaining and morphometric analysis. The mice were anesthetized,
and the graft-bearing kidney was harvested after perfusion with 1% para-
formaldehyde. After overnight ﬁxation in 4% paraformaldehyde, the graft was
processed for parafﬁn blocks. Each sectionwas processed for hematoxylin-eosin
or immunoﬂuorescence, and digital images were obtained using either a Zeiss
inverted microscope or a Zeiss LSM 710 confocal microscope (Carl Zeiss,
Thornwood, NY). The entire grafts from each animal were serially cut, and 40
sections per graft were analyzed for b-cell mass and vasculature. For other
immunostaining experiments, 10 sections per graft were analyzed. All anti-
bodies used for immunohistochemical staining were tested with secondary
antibody only as negative control to conﬁrm their speciﬁcity at each ex-
periment, and some antibodies to detect human sample speciﬁcally were also
evaluated on the cross- reactivity between human, porcine, and mouse tis-
sues (Supplementary Fig. 1). Morphometric measurements and analysis were
performed using ImageJ software (http://rsb.info.nih.gov/ij). The result of the
morphometric analysis was expressed as the mean signal density or in-
tegrated signal density (the summation of the mean signal density for each
pixel of the intended area).
Antibodies and primer sequences. The following antibodies were used for
the experiments. Goat anti–VE-cadherin, goat anti-CD34, goat anti–PECAM-1,
rabbit anti–PECAM-1 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-
insulin, biotin-conjugated BS1-lectin, biotin-conjugated UEA1-lectin, TRITC-
BS1-lectin, ﬂuorescein isothiocyanate (FITC)-UEA1-lectin, mouse anti-glucagon,
rabbit anti-laminin (all from Sigma), mouse anti–PECAM-1, mouse anti-vWF,
guinea pig anti-insulin (Dako, Carpinteria, CA), goat anti–VEGF-A, goat anti-
angiopoietin 1 (Ang1), goat anti-VEGFR2 (R&D Systems, Minneapolis, MN),
rabbit anti–hypoxia probe (Hypoxyprobe), rabbit anti-Ki67 (Abcam, Cam-
bridge, MA), and goat anticollagen IV (Col IV) (Millipore, Billerica, MA) anti-
bodies were used as primary antibodies. All secondary antibodies were from
Jackson ImmunoResearch (West Grove, PA). Hoechst and Sytox blue (Molecular
probe, Eugene, OR) were used for nuclear staining. For the primer sequences,
see Supplementary Table 1. For primer sequences, see Supplementary Table 1.
Statistical analysis. Continuous and categorical variables are presented as
means6 SEs. Comparisons between two groups were performed with unpaired
t tests. All statistical analyses were performed with SPSS 17.0 (SPSS, Chicago,
IL), and P , 0.05 was considered statistically signiﬁcant.
RESULTS
Better glycemic control and islet engraftment with
EPC cotransplantation. We isolated EPCs from human
cord blood and conﬁrmed them with EPC-speciﬁc surface
markers (Fig. 1A–B). To evaluate whether EPC cotrans-
plantation could enhance engraftment in islet transplan-
tation, we transplanted 7,000 IEQ porcine islets, either with
(the islet-EPC group) or without (the islet-only group)
5 3 105 human cord blood–derived EPCs, into the renal
capsules of diabetic nude mice. Nondiabetic mice with sham
transplantation (the non-DM sham group) and diabetic mice
with sham transplantation (the DM-sham group) were used
as controls. In contrast to the persistent hyperglycemia in
the DM-sham group, the islet-EPC group showed a gradual
decrease in blood glucose, ﬁnally reaching normoglyclemia
(,200 mg/dL) at ;11 days. Although blood glucose de-
creased slightly in the islet-only group, it failed to reach
normoglycemia over a 5-week period. At 5 weeks after
transplantation, the graft-bearing kidney was removed. The
blood glucose of both the islet-only and islet-EPC groups
increased to 550 mg/dL, indicating that the improved gly-
cemic control in the islet-EPC group was derived from the
transplanted islets and not from the regeneration of rem-
nant pancreatic islets of the host (Fig. 1C). The DM-sham
group gradually lost weight, eventually resulting in death.
However, the incremental weight gain in the islet-EPC
group was similar to that of the non-DM sham group. The
islet-only group also gained weight, but there was a distinct
lag behind the islet-EPC group (Fig. 1D). We investigated
whether the improved glycemic control in the islet-EPC
group was associated with insulin production from the
transplanted islets. The islet-EPC group showed a higher
serum porcine insulin level than the islet-only group under
fasting conditions (islet-EPC vs. islet-only 21.5 6 2.0 vs.
12.2 6 2.6 ng/mL, respectively; P , 0.05) (Fig. 1E). Histo-
logical examination of the graft-bearing kidneys demon-
strated larger islet mass, as assessed by the insulin-positive
area per given ﬁeld in the islet-EPC group compared with
that of the islet-only group (islet-EPC vs. islet-only 26.1 6
1.6 vs. 19.8 6 1.8%; P , 0.05) (Fig. 1F and G) at day 35.
Additionally, the porcine insulin mRNA level of the graft site
was also found to be higher in the islet-EPC group than in
the islet-only group by q-PCR (islet-EPC vs. islet-only 6.6 6
0.9 vs. 1.0 6 0.5-fold; P , 0.05) (Fig. 1H). This difference
was not the result of the decrease in connective tissue area
or other endocrine cell fractions because there were no
difference in the Col IV–positive connective tissue or the
glucagon/somatostatin-positive endocrine cell areas in
insulin-positive area was measured, calculated as percent area of the insulin-positive area, and then presented as arbitrary units with the value of
the islet-only group set to 1 (n = 4). I: The graft sites of each mouse at day 10 were dissected, harvested, and analyzed for PECAM-1 with primers all
for human, porcine, and mouse by q-PCR (n = 4). All of the q-PCR data are presented in arbitrary units after normalization to glyceraldehyde-3-
phosphate dehydrogenase, with the islet-only group set to 1. The data are presented as means6 SE. *P< 0.05 vs. the islet-only group. White dotted
lines show the territory of the graft site. Scale bars, 50 mm in A and 100 mm in C and G. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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either group (Fig. 1I and J). These ﬁndings indicate that
EPC cotransplantation may be helpful for encouraging
successful islet engraftment, ultimately leading to better
glycemic control.
Rapid revascularization of the transplanted islets by
EPC cotransplantation. To clarify how the EPC cotrans-
plantation enhanced the islet engraftment, we evaluated the
process of neovascularization in the transplanted islets us-
ing BS1-lectin immunostaining. The BS1-lectin immunos-
taining was ﬁrst conﬁrmed to reach the smallest capillaries
inside of the islets in porcine pancreas and islet graft
(Supplementary Fig. 2) (22). The islet-EPC group exhibited
a signiﬁcantly greater total blood vessel density and more large
vessels ($5 mm in diameter) at 5 weeks after transplantation.
VE-cadherin, another vascular marker, immunostaining of the
graft site was consistent with the BS1-lectin–staining re-
sults. However, the capillary density in the graft was not
different between the islet-EPC group and the islet-only
group at day 35 (Fig. 2A and B). Therefore, we evaluated the
rate of revascularization between the two groups from an
earlier period of transplantation. Although the difference of
capillary density between the two groups became in-
signiﬁcant by day 35, the islet-EPC group showed higher
branching-vessel density at days 3 and 14 and higher cap-
illary density at days 14 and 21 than the islet-only group
(Fig. 2C–F). Quantiﬁcation of the total lectin-positive area,
branching-vessels area, and the capillary area in the graft
site at each time point corroborated the histological analysis,
suggesting that the EPC cotransplantation does not increase
capillary density within the graft at full revascularization but
may enhance early revascularization rate (Fig. 2D–F). For
a more accurate quantiﬁcation of the neovascularization,
we also evaluated PECAM-1–positive capillary density per
insulin-positive area at day 21 in both groups. The PECAM-
1–positive intraislet capillary density was higher in the islet-
EPC group than in the islet-only group, indicating that
intraislet capillary formation was also hastened in the islet-
EPC group (Fig. 2G andH). In addition, the level of PECAM-1
mRNA in the graft site was also higher in the islet-EPC group
than in the islet-only group, indicating that the rapid revas-
cularization found in the morphological analysis matched the
gene expression characteristics (Fig. 2I).
Mechanism underlying the EPC-induced neovascular-
ization after islet transplantation. Next, we examined
the mechanism of the EPC contribution to rapid islet neo-
vascularization. We investigated whether the EPCs might
induce the production of angiogenic factors, such as VEGF-A
and Ang1. In the porcine pancreas, VEGF-A is expressed
predominantly in islet b-cells (Fig. 3A). Even though the
increase in Ang1 expression was not statistically signiﬁcant
(Supplementary Fig. 3), VEGF-A expression was signiﬁ-
cantly higher in the islet-EPC group than in the islet-only
group at day 14 (Fig. 3B). This ﬁnding was supported by the
higher mean signal density of VEGF-A in the insulin-positive
area in the islet-EPC group than in the islet-only group
(islet-EPC vs. islet-only 2.1 6 0.1 vs. 1.0 6 0.1-fold, respec-
tively; P , 0.05) (Fig. 3C). In addition, the porcine VEGF-A
mRNA expression in the graft site was elevated in the islet-
EPC group compared with the islet-only group, consistent
with the histological analysis (islet-EPC vs. islet-only 1.4 6
0.2 vs. 1.0 6 0.1-fold; P , 0.05) (Fig. 3D). To evaluate
whether the EPCs directly stimulated the production of
angiogenic factors from the islets, human-origin EPCs were
cocultured with mouse islets, and the mRNA levels of sev-
eral angiogenic factors were evaluated with mouse-speciﬁc
primers. Importantly, the islets cocultured with EPCs
produced signiﬁcantly more VEGF-A mRNA than did the
control islets (islet-EPC vs. islet-only 3.6 6 0.2 vs. 1.0 6 0.1-
fold; P , 0.01). Other angiogenic factors, such as VEGF-C,
VEGF-D, Ang1, and Ang2, showed only small changes. The
receptors for angiogenic proteins, such as the VEGFR2,
VEGFR3, and Tie2 receptor, showed only slight changes
(Fig. 3E and F). There was also more VEGF-A production
from the EPC-cocultured islets when porcine islets were
used instead of mouse islets (islet-EPC vs. islet-only 1.9 6
0.1 vs. 1.0 6 0.2-fold; P , 0.05) (Fig. 3G). In addition, we
evaluated whether EPCs could contribute to the en-
hanced revascularization rate by direct incorporation into
the vasculature. To discriminate between the blood ves-
sels originating from the cotransplanted EPCs and those
from the islets and the recipient, we immunostained the
specimens with human-speciﬁc PECAM-1 antibody for
EPCs and with BS1-lectin for islets or recipient-origin en-
dothelial cells (23,24). Among BS1-lectin–positive vessels,
only a small number was positive for human-speciﬁc
PECAM-1 at day 10. The proportion of these cells de-
creased further at day 35 (Supplementary Fig. 4). These
ﬁndings suggest that direct incorporation of EPCs into the
host vasculature may not play a major role in the graft
revascularization. Rather, EPC cotransplantation may in-
duce rapid revascularization at an early period after
transplantation mainly by stimulation of angiogenic cyto-
kine secretion from the graft.
Improvement of graft perfusion and recovery of
ischemia by EPC cotransplantation. Next, we evalu-
ated whether the rapid and effective revascularization in
the islet-EPC group would lead to an actual increase in the
perfusion of the transplanted islets. The mice were injected
with TRITC-conjugated BS1-lectin before harvesting the
kidney. At day 3, there were few TRITC-positive vessels in
the grafts of either group. However, at days 14 and 21, we
found more TRITC-positive functional vessels in the islet-
EPC group than in the islet-only group (Fig. 4A and B). To
clarify the process of functional vessel formation, we
stained the TRITC-BS1-lectin–perfused graft with FITC-
BS1-lectin. Similar to the data shown in Fig. 2C, the islet-
EPC group showed more FITC-lectin–positive endothelial
cells and branching vessels at day 14. Some of these ves-
sels were also TRITC-lectin positive, indicating perfused
vessel, as shown by the yellow color in the merged image,
and also suggesting that individual endothelial cells inﬁl-
trated the graft initially and then began to form functional
perfusing blood vessels (Fig. 4C and D). To determine
whether the increase in functional blood vessels could
lead to improvement in graft ischemia, tissue hypoxia was
assessed using the Hypoxyprobe kit. At day 14, the grafts
in the islet-EPC group began to recover from hypoxia, as
shown by the weak-positive signal of the Hypoxyprobe,
which coincided with better graft perfusion compared with
the islet-only group (Fig. 4E and F). Collectively, these
data demonstrate better vessel perfusion and effective
relief of graft ischemia in the islet-EPC group compared
with the islet-only group.
b-Cell proliferation in EPC cotransplanted group
associated with more basement membrane protein
and HGF production. Finally, we evaluated whether the
improvement in islet engraftment might have resulted from
a higher proliferating capacity of the b cells caused by the
EPC cotransplantation. The number of Ki67/insulin–double-
positive proliferating b-cells began to increase at day 3 in
the islet-EPC group, peaked at day 14, and returned to
baseline at day 35. By contrast, the islet-only group showed
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fewer proliferating b cells from day 3 to day 35, suggesting
that EPC cotransplantation enhanced b-cell proliferation
(Fig. 5A–C). In addition, there were fewer transferase-
mediated dUTP nick-end labeling/insulin–double-positive
apoptotic cells in the islet-EPC group than in the islet-only
group (Supplementary Fig. 5). The higher proliferation
rate of the b cells was associated with a higher engrafted
b-cell mass, as shown by the insulin-positive area at day 35
(Fig. 5D).
Because matrix proteins forming basement membranes
are a possible factor for b-cell proliferation and survival
(5,25–28), we assessed whether the EPC cotransplantation
would lead to more extensive basement membrane pro-
duction at day 14, when blood vessel grew more rapidly in
the islet-EPC group. First, we evaluated the expression
pattern of Col IV, the major basement membrane protein for
porcine islets. Col IV was mainly expressed in the vicinity
of the BS1-lectin–positive endothelial cells (Supplementary
Fig. 6). To evaluate the formation of the basement mem-
brane after transplantation, we visualized Col IV and laminin
(another important basement membrane protein) in the graft
site at day 14. Consistent with the rapid neovascularization,
FIG. 3. The mechanisms underlying the EPC-induced neovascularization in islet transplantation. A: The porcine pancreas was visualized with
VEGF-A, insulin, and BS1-lectin immunostaining. B and C: Graft-bearing kidneys were removed at day 14, and the VEGF-A expression was visu-
alized together with the BS1-lectin and insulin immunostaining. B: Representative images of the graft. C: The mean VEGF-A signal density from the
insulin-positive area was measured and presented in arbitrary units (AU), with the value of the islet-only group set to 1 (n = 4). D: At day 10, the
graft site of each mouse was dissected, harvested, and analyzed for VEGF-A by q-PCR with porcine-speciﬁc primers. The data are presented in
arbitrary units after normalization to glyceraldehyde-3-phosphate dehydrogenase, with the value for the islet-only group set to 1 (n = 4). E–G:
Mouse islets (E and F) or porcine islets (G) were cultivated with human EPCs for 48 h or 4 days, respectively, and harvested for RNA extraction.
Mouse and porcine islets were cultivated without EPCs under the same conditions to serve as controls. The angiogenic growth factors and their
receptors were evaluated by q-PCR with mouse-speciﬁc (E and F) and porcine-speciﬁc (G) primers. The data are presented in arbitrary units after
normalization to mouse-speciﬁc b-actin for the mouse islets or to porcine-speciﬁc glyceraldehyde-3-phosphate dehydrogenase for the porcine
islets, with the values for the islet-only group set to 1 (n = 3). The data are presented as means 6 SE. *P < 0.05 vs. the islet-only group. Scale bars,
100 mm. (A high-quality color representation of this ﬁgure is available in the online issue.)
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the Col IV or laminin deposition was more extensive in the
islet-EPC group, suggesting that the EPC cotransplantation
may have extended the contact area between the b cells
and the basement membrane, resulting in increased b-cell
proliferation (Fig. 6A–D). Because HGF is another factor
that can induce b-cell proliferation (29–33) and HGF might
perform such a role by communication with islet endothelial
cells (32), HGF expression from EPCs was evaluated in
vitro and in vivo. The HGF mRNA level was higher in the
graft site of the islet-EPC group than in the islet-only group
(islet-EPC vs. islet-only 2.6 6 0.2 vs. 1.0 6 0.2-fold, re-
spectively; P # 0.01) (Fig. 6E). To identify the source of
HGF, we performed porcine islet/human EPC coculture
experiments in vitro. The EPCs cocultured with islets
FIG. 4. Improvement of graft perfusion and recovery from ischemia by EPC cotransplantation. A and B: The functional blood vessels in the graft
were analyzed with TRITC-BS1-lectin perfusion at days 3, 14, and 21 posttransplantation. A: Representative images of the perfused vessels in the
graft site. B: The TRITC-positive vessel area in A was calculated as the percentage of the total graft area, and then the values are presented in
arbitrary units (AU) with the value of the islet-only group set at day 3 to 1 (n = 4). C and D: The total blood vessels were identiﬁed with FITC-BS1-
lectin staining together with functional vessels identiﬁed with TRITC-BS1-lectin perfusion at day 14. C: Representative images of functional
vessels among the entire vessels are presented in the left panel. The right panels show the magniﬁcation view of the insert in the white dotted
rectangle. D: TRITC-positive functional vessel area and FITC-positive total vessel area were calculated as the percentage of the total graft area,
and then the values were presented in arbitrary units with the value of total vessel for the islet-only group set to 1 (n = 4). E and F: The graft
ischemia was evaluated by the Hypoxyprobe-positive signal at day 14 in both groups. E: Representative images of the Hypoxyprobe-positive area in
the graft are shown, together with the TRITC-BS1-lectin and insulin immunostaining. F: The mean signal density of the Hypoxyprobe from the
insulin-positive area was measured and presented in arbitrary units, with the value of the islet-only group set to 1 (n = 4). The data are presented
as means 6 SE. *P < 0.05 vs. the islet-only group. White dotted lines show the territory of the graft site. Scale bars, 100 mm. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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produced more HGF than the EPCs cultured alone, sug-
gesting that the cross-talk between islet and EPC may in-
duce the production of key factors for b-cell proliferation,
such as HGF from EPCs (islet-EPC vs. islet-only 3.2 6 0.2
vs. 1.0 6 0.1-fold; P # 0.01) (Fig. 6F). Therefore, EPC
cotransplantation may also enhance islet engraftment by
providing the basement membrane and/or production of
HGF that is required for b-cell proliferation.
DISCUSSION
The most important ﬁnding of this study is that EPC
cotransplantation can be a novel and clinically applicable
strategy for enhancing islet engraftment in islet trans-
plantation. Cotransplanted EPCs hastened the rate of re-
vascularization of the graft, which improved the functional
status of vasculature (i.e., better perfusion and recovery
from ischemia) and ﬁnally resulted in a greater engrafted
b-cell mass. The transplanted EPCs actively participated in
the neovascularization process mainly by stimulating VEGF-A
production from the graft. Furthermore, cotransplanted
EPCs induced b-cell proliferation, possibly by inducing
production of matrix proteins and HGF.
Impaired and delayed revascularization of the graft is
one of the main causes of graft failure after islet trans-
plantation (2). Several attempts to overcome this problem
have shown promising results but are also associated with
problems that hinder their direct clinical application. The
direct application of angiogenic factors, such as VEGF-A
and Ang1 (34,35), and cotransplantation of mesenchymal
stem cells (36) have shown improved angiogenesis, resulting
in enhanced islet survival. Nevertheless, replacing angio-
genic factors (either by gene transfer or direct application)
is not free of safety concerns and/or is limited by the rela-
tively short half-life of the factors (37,38). Mesenchymal
stem cells may stimulate angiogenesis, but the risk of un-
expected tumor development may be a concern (39,40). On
the contrary, EPC cotransplantation may be a more effec-
tive, more physiological, and safer strategy for inducing
neovascularization in islet transplantation.
In this study, cotransplanted EPCs hastened the rate of
revascularization at the early stage of transplantation.
However, the ﬁnal capillary density per area in the graft
site became similar between the islet-EPC and islet-only
groups. This pattern of revascularization is similar to the
recent ﬁndings by Berggren and colleagues, who evaluated
FIG. 5. EPC cotransplantation is associated with b-cell proliferation. A–C: The transplanted islets were evaluated for proliferation by Ki67/insulin
double staining at days 3, 14, and 35. A: The Ki67/insulin–double-positive proliferating b cells were visualized at each time point (arrow). Hoechst
stain was used to distinguish the nucleus. B: Magniﬁcation views of the inserts within the white dotted line at day 14. C: The number of Ki67-
positive cells among the insulin-positive cells in the total given area was counted (0.18 mm2) (n = 4). D: The integrated density of the insulin-
positive area of the total given area (0.18 mm2) was measured and presented in arbitrary units (AU), with the value of day 3 for the islet-only group
set to 1 (n = 4). The data are presented as means 6 SE. *P < 0.05 vs. the islet-only group. Scale bars, 100 mm in A and 50 mm in B. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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the contribution of intraislet endothelial cells in islet re-
vascularization (41). The contribution of exogenously
transplanted EPCs in our series of experiments is rather
analogous to the more intraislet endothelial cells in freshly
transplanted islets. The signiﬁcant difference of vascular
density at an earlier time point (days 14–21), the blood
glucose control, and the islet survival coinciding with this
time line suggest that the EPCs may play a critical role in
enhancing revascularization at an earlier time point after
transplantation. Therefore, the role of EPCs can be to trigger
or hasten the initial revascularization process.
An important ﬁnding of our study is that we have pro-
posed the existence of cross-talk between the transplanted
islets and the endothelial cells and that this communica-
tion can be successfully harnessed for superior results in
islet transplantation. In terms of revascularization, we found
that the transplanted islets were the major producers of
VEGF-A (42), a well-known proangiogenic factor that attracts
VEGFR2-expressing endothelial cells and circulating
EPCs (43) (Fig. 3B–D). The enhanced initial islet survival
by rapid revascularization with EPCs may augment islet
survival, resulting in more VEGF-A production from the
surviving islets, and ﬁnally enhanced graft angiogenesis.
VEGF-A may also be effective at stimulating HGF produc-
tion from the vessels around the islets (32), which can also
stimulate angiogenesis (44–46) and b-cell proliferation
(29–33). Put together, islets may actively enhance revas-
cularization by secretion of VEGF-A. In turn, enhanced
angiogenesis by VEGF-A may enhance islet engraftment,
which results in more VEGF-A production from the re-
maining surviving islets.
Alternatively, in terms of islet survival, augmented re-
vascularization by the EPC cotransplantation may provide
survival/proliferation cues to the islets. Both endothelial
cells and b cells produce matrix proteins (47), and the
matrix proteins are known to enhance insulin production
FIG. 6. b-Cell proliferation in the EPC-cotransplanted group is associated with more basement protein and HGF production. A–D: At day 14, the
BS1-lectin–positive blood vessels and Col IV– or laminin-positive basement membrane were visualized. The insulin was immunostained to dis-
tinguish the graft site. The representative images for Col IV (A) and laminin (C) are shown. White dotted lines show the territory of the graft site.
Scale bars, 100 mm. The Col IV–positive (B) and the laminin-positive (D) areas from total graft area were calculated as a percentage of the total
graft area and then presented as arbitrary units (AU), with the value of the islet-only group set to 1 (n = 4). E and F: The graft sites of day 10 from
each mouse in vivo (E) and human EPCs cocultured in vitro with or without porcine islets (F) were harvested. The specimens were analyzed for
HGF by q-PCR using primers that functioned for all three species (human, porcine, and mouse) in E and for human exclusively in F. The data are
presented in arbitrary units after normalization to glyceraldehyde-3-phosphate dehydrogenase, with the value for the islet-only group set to 1 in E
and with the value for the EPC-only group set to 1 in F (n = 4). The data are presented as means6 SE. *P< 0.05 vs. the islet-only group in B,D, and
E and vs. the EPC-only group in F. (A high-quality color representation of this ﬁgure is available in the online issue.)
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and b-cell proliferation (25–28). Consistent with these
previous ﬁndings, signiﬁcantly better angiogenesis around
the graft and higher engrafted b-cells with EPC cotrans-
plantation was associated with a signiﬁcant increase in the
basement membrane proteins Col IV and laminin. In ad-
dition, enhanced VEGF-A production from the islets can
itself be a direct islet survival/growth factor by an auto-
crine effect (48). Furthermore, consistent with a previous
report demonstrating the prosurvival effect of HGF on islet
proliferation (29–33), our in vitro and in vivo ﬁndings
showed that higher HGF production from endothelial cells
was associated with higher b-cell proliferation in the islet-
EPC group. Therefore, EPC cotransplantation may aug-
ment islet proliferation by multiple mechanisms: basement
membrane production and VEGF-A/HGF secretion.
Our study has several unique points compared with pre-
vious works. First, we have suggested a positive feedback
effect between revascularization and islet engraftment,
which involves angiogenic cytokines and matrix proteins.
This communication between vasculature and graft survival
was enhanced when EPCs were transplanted together
with the islets. Second, our study demonstrated that EPCs,
which are a rather homogenous cell group compared with
bone marrow–derived cells, can be another useful adjunct
cell type to boost islet engraftment. Cotransplantation of
bone marrow–derived cells with islets is being intensely
explored as a strategy to establish microchimerism in graft
recipients that could lead to the reduction of immunosup-
pression (49) as well as to the enhancement of revascu-
larization (14). Our studies suggest that cotransplantation of
EPCs with islets might also be effective in reducing instant
blood-mediated inﬂammatory reaction (50) and in enhanc-
ing early revascularization, proliferation, and ultimately
engraftment of islets. Third, from a more practical view-
point for clinical application, EPCs can be obtained rather
easily either from peripheral blood or from a bank, such as
cord blood (10). This may be important because the EPCs
of patients with diabetes are essentially defective in both
number and revascularization function (15,16). Therefore,
our study provides a potential strategy to improve the efﬁ-
cacy of islet transplantation by enhancing early revas-
cularization rate that might be applied into clinical practice.
In conclusion, EPC cotransplantation is a new and
promising therapeutic modality for enhancing islet en-
graftment by rapid revascularization. The results of this
study may warrant future clinical trials.
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